Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.
about
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsCMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant RecipientsCytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic TransplantationCytomegalovirus infection in transplant recipientsCMV: Prevention, Diagnosis and TherapyClinical utility of viral load in management of cytomegalovirus infection after solid organ transplantationState-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinicianInfection in Organ Transplantation.Current characteristics and outcome of cytomegalovirus infections after kidney transplantation.Management of cytomegalovirus infection and disease in liver transplant recipients.Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients.Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation.Use of leflunomide in renal transplant recipients with ganciclovir-resistant/refractory cytomegalovirus infection: a case series from the University of Chicago.Cytomegalovirus disease in African-American kidney transplant patientsProphylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.Is prevention the best treatment? CMV after lung transplantation.Update on cytomegalovirus infections of the gastrointestinal system in solid organ transplant recipients.Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment.Clinical aspects of cytomegalovirus antiviral resistance in solid organ transplant recipients.Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients.Induction therapy in pancreas transplantation.Emerging cytomegalovirus management strategies after solid organ transplantation: challenges and opportunities.Cytomegalovirus infection in liver transplant recipients: updates on clinical managementThe efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An OverviewA risk-stratified approach to cytomegalovirus prevention in pediatric solid organ transplant recipients.The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management.First face composite-tissue transplant recipient successfully treated for cytomegalovirus infection with preemptive valganciclovir treatment.Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients.Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and/or film-coated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease.Complexity of Host Micro-RNA Response to Cytomegalovirus Reactivation After Organ Transplantation.Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.Role of secondary prophylaxis with valganciclovir in the prevention of recurrent cytomegalovirus disease in solid organ transplant recipients.Cytomegalovirus prophylaxis in pediatric kidney transplantation: the Dutch experience.
P2860
Q24200697-54756A0D-DB99-4DA7-8BE8-B9362E445B8FQ24200991-674B68BF-BBC0-4665-8A1C-A843BB45604DQ26768473-FFDDB080-A958-478B-8986-FCF2EA2592EAQ26768477-D672A3AC-9CAF-487C-BA66-FA4C2975304BQ26801802-FAF83E79-B9D7-4A4B-8D79-A1F970E03603Q26824869-A0046EDC-C731-4691-8564-8CA7EA901434Q26826856-194C0BBD-2AE1-4375-9FBA-5539FD64F662Q27014778-92358B38-9DB1-4F18-81BC-C1D388F4D65DQ30238810-598ED446-14D8-404F-8A55-4B767FCD49B0Q33416126-0D710159-E6C8-4C87-8FCA-3F9D50FACCFFQ33845124-7A2D79FC-9604-4953-8FAA-05C8A00A0F5AQ34065300-CACD4F79-F207-43CA-A855-716899721052Q35051236-01CEF107-299E-46E2-AD49-9BE59BF21236Q35196219-3B32F128-DF7F-4977-863D-BB01C813C582Q35592509-61C6EBC3-FBD0-44A1-9C9C-853CB056195CQ36614140-E1452A19-5911-447A-B3F1-0D97BFB07F14Q37203522-C667112D-99C3-4ECA-AFA7-C863F81B1632Q37949634-8850F174-A159-4F69-A218-73A634DAE526Q37954420-B8FA281C-B674-4B14-86F3-3182B739D025Q37962447-7DAB8916-D057-422E-9942-E179364B3211Q37965695-8F4AB80A-8D8E-45B3-857F-5C4843418E31Q38044829-314048B8-5F1D-4CE8-B64A-79744BC6A242Q38067694-4AF1EDEE-A381-49AD-BD3A-39E95446AC6EQ38099432-B4065737-CF1B-4005-B879-4C3AA2792DC1Q38106742-64E793C8-4412-4548-A669-74FE4E99E979Q38225475-01BE87C8-1226-46AE-82D7-17AF271E65C5Q38242802-9A55F2A5-8276-47AD-B8BD-B515779BD309Q38254037-04CD49CA-C8CB-4566-B4AB-F80A0704D985Q38599972-3D90DAD3-733E-4550-8DD5-CFB68E3AC73CQ38938297-703F24AA-230F-45E3-81EB-B6426EB4D587Q39321579-54A33443-E1A4-487E-A290-F3AA279659D8Q39405795-AC3622DB-72F4-4ADD-8F19-FBEAF884988FQ39659062-B3F00575-F631-4438-B1AA-5182E52365DFQ40426465-7745247D-C943-49ED-8381-82B3DC55EE84Q40501883-109C11ED-19BE-4AAC-9B97-C60B91BC974CQ40955529-E7A196BE-4DCE-49B8-8F71-E529DB657B0DQ41128262-8B047C7F-9A06-46D0-AE51-9D0D71AF3E32Q41342348-F26F9DE3-C36B-4B2D-B633-A8B58FBEE041Q41987171-93EA2762-05F7-41FD-902C-E42F0D48FA7DQ42281180-97FAA3FC-904A-4036-9A9B-D0F09B8F4C0B
P2860
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Extended valganciclovir prophy ...... r results of the IMPACT study.
@en
Extended valganciclovir prophy ...... r results of the IMPACT study.
@nl
type
label
Extended valganciclovir prophy ...... r results of the IMPACT study.
@en
Extended valganciclovir prophy ...... r results of the IMPACT study.
@nl
prefLabel
Extended valganciclovir prophy ...... r results of the IMPACT study.
@en
Extended valganciclovir prophy ...... r results of the IMPACT study.
@nl
P2093
P1433
P1476
Extended valganciclovir prophy ...... r results of the IMPACT study.
@en
P2093
Ajit P Limaye
Atul Humar
Emily A Blumberg
Flavio Vincenti
Ingeborg A Hauser
Jane A L Ives
Mahdi Farhan
Patrick Peeters
P304
P356
10.1097/TP.0B013E3181FF1493
P577
2010-12-01T00:00:00Z